ARAP2 is a phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3)-dependent Arf6 GTPase-activating protein (GAP) that regulates actin cytoskeleton dynamics and focal adhesion formation 1. The protein contains both ArfGAP and RhoGAP domains, functioning as an Arf6 GAP while binding RhoA-GTP without exhibiting RhoGAP activity 1. ARAP2 promotes focal adhesion growth by converting Arf6·GTP to Arf6·GDP, thereby suppressing Rac1 activation 2. Unlike ACAP1, another Arf6 GAP with opposing effects, ARAP2 localizes to APPL1-positive endosomes and slows integrin β1 internalization, regulating integrin trafficking through distinct endosomal compartments 3. Clinically, dysregulated ARAP2 expression contributes to disease pathogenesis. Circular RNA derived from ARAP2 (circ-ARAP2) is upregulated in esophageal squamous cell carcinoma, promoting tumor progression through the miR-761/FOXM1 axis, affecting cancer stemness and epithelial-mesenchymal transition 4. ARAP2 also regulates interferon-gamma signaling; tyrosine 415 phosphorylation enables ARAP2 to interact with and restrict the negative regulator SOCS1, enhancing JAK-STAT signaling and exacerbating inflammation during viral infection 5. Genetic variants in ARAP2 are associated with fatty liver development in geese, suggesting involvement in lipid metabolism and potential relevance to non-alcoholic fatty liver disease 6.